Poseida Therapeutics Inc [PSTX] stock prices are down -0.11% to $9.50 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PSTX shares have gain 0.53% over the last week, with a monthly amount glided 244.20%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Poseida Therapeutics Inc [NASDAQ: PSTX] stock has seen the most recent analyst activity on December 02, 2024, when Piper Sandler downgraded its rating to a Neutral but kept the price target unchanged to $10 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on January 04, 2023, and set its price target to $15. On January 07, 2022, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $24 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $40 on May 18, 2021. William Blair initiated its recommendation with a Outperform. Piper Sandler started tracking with a Overweight rating for this stock on August 04, 2020, and assigned it a price target of $30. In a note dated August 04, 2020, BofA Securities initiated an Buy rating and provided a target price of $20 on this stock.
The stock price of Poseida Therapeutics Inc [PSTX] has been fluctuating between $1.87 and $9.58 over the past year. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Poseida Therapeutics Inc [NASDAQ: PSTX] shares were valued at $9.50 at the most recent close of the market. An investor can expect a potential return of 5.26% based on the average PSTX price forecast.
Analyzing the PSTX fundamentals
The Poseida Therapeutics Inc [NASDAQ:PSTX] reported sales of 150.86M for trailing twelve months, representing a surge of 667.19%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.41%, Pretax Profit Margin comes in at -0.4%, and Net Profit Margin reading is -0.39%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.71 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.47 points at the first support level, and at 9.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.54, and for the 2nd resistance point, it is at 9.58.
Ratios To Look Out For
It’s worth pointing out that Poseida Therapeutics Inc [NASDAQ:PSTX]’s Current Ratio is 3.20. In addition, the Quick Ratio stands at 3.20 and the Cash Ratio stands at 0.63. Considering the valuation of this stock, the price to sales ratio is 6.14, the price to book ratio is 10.61.
Transactions by insiders
Recent insider trading involved Gergen Mark J, Executive Chairman, that happened on Dec 10 ’24 when 30000.0 shares were sold. Executive Chairman, Gergen Mark J completed a deal on Nov 26 ’24 to sell 30000.0 shares. Meanwhile, Director MARK GERGEN bought 0.12 million shares on Nov 26 ’24.
